全球微生态药物研发现状及发展趋势 *

微生态药物在许多复杂性和慢性疾病中显示出极大的潜力,逐渐成为国际制药行业的新趋势。基于科睿唯安旗下的Cortellis数据库,采用定量分析和专家智慧相结合的方法,从总体研发现状、主要国家/地区、主要适应症、重点企业研发管线、重点在研药物、商业化交易多个维度展现全球微生态药物的研发和商业化全景。分析结果显示:全球共有142个在研微生态药物,其中49个药物处于临床阶段。美国在微生态药物研发和商业化方面遥遥领先,其数量占在研药物总量的70%。在研药物的适应症主要集中于炎症性肠病、艰难梭菌感染、溃疡性结肠炎等肠道感染性疾病。4D pharma公司的在研药物数量最多,微生态药物重点研发企业均建立起核心技术平台。处于临床3期的微生态药物共有7个,全球微生态药物商业化交易共有303起,最大的交易金额是27.8亿美元。未来,微生态药物有望在更难被人类征服的肿瘤和神经系统疾病方面取得突破性进展。     

乳酸菌基因改造技术研究进展

乳酸菌是一类革兰氏阳性、不产芽孢、兼性厌氧、发酵多种碳源产乳酸的重要工业微生物之一,广泛应用于食品、医药及化学品的生产当中。随着乳酸菌工业化应用范畴的不断拓展,乳酸菌生理生化特性、酸耐受特性,代谢途径及产酸调控机理的研究受到广泛关注。因此,建立稳定、高效的乳酸菌基因编辑方法,借助基因编辑技术来解析代谢关键基因及基因网络的功能,调控代谢途径,十分必要。对乳酸菌基因编辑技术的研究进展做一综述,并对乳酸菌基因编辑技术的未来研究方向进行展望。     

东北红松纯林菌根外生菌根真菌群落与环境因子的相关性

外生菌根是木本植物根系与真菌形成的共生结构,外生菌根真菌在红松等外生菌根树种的定植与森林生态系统的保持方面起到至关重要的作用。明确菌根系统内外生菌根真菌群落组成是揭示菌根共生机制的前提条件。本研究利用Illumina Hiseq测序平台对生长季内红松纯林内根围土壤及菌根样品ITS2区进行高通量测序,分析其外生菌根真菌群落结构随季节的变化规律,同时通过统计学的方法分析了红松根系微生态中外生菌根真菌群落结构组成变化与其他生物因素、非生物因素的相关性。结果如下：（1）从6月份到10月份,5个月的菌根样品测序共得到741个真菌OTUs,利用FUNGuild数据库分析,其中85个OTUs归类为外生菌根真菌,优势属（相对丰度>5）为蜡壳菌属Sebacina、乳牛肝菌属Suillus、Meliniomyces、红菇属Russula、棉革菌属Tomentella、须腹菌属Rhizopogon和缘腺革菌属Amphinema。6月份菌根中外生菌根真菌的多样性最大,显著高于其他月份。（2）红松林外生菌根真菌群落组成受到土壤pH、有效磷含量、有效钾含量和土壤有效氮含量的影响,它们与外生菌根真菌优势属相对丰度呈现正相关或负相关。（3）根围土壤内真菌是影响红松根系外生菌根真菌相对丰度的另一重要因素,其中,包括普可尼亚属Pochonia、产丝齿菌属Hyphodontia、镰刀菌属Fusarium、Collembolispora、枝穗霉属Clonostachys、Apodus、鹅膏属Amanita在内的土壤真菌与根内外生菌根真菌的相对丰度呈线性关系。同时,超过85%的根内外生菌根真菌与同一取样地的土壤共有,可以认为侵染和扩散是红松根内外生菌根真菌群落形成的主要方式,同时兼有植物根系的选择,因为根内并不包括所有土壤中存在的外生菌根真菌,其机制需要进一步人工模拟试验验证。     

一株特殊生境荒漠药用植物沙蓬内生真菌Rhinocladiella similis中苯甲酸大环内酯化合物

从一株特殊生境荒漠药用植物沙蓬的内生真菌Rhinocladiella similis中分离得到4个苯甲酸大环内酯化合物,包括2个新化合物rhinoclactones E（2）和F（1）、2个已知化合物8,9-dihyrogreensporone D（3）和8,9-dihydrogreensporone A（4）。基于高分辨质谱与核磁共振谱数据以及相关文献比对,确定了新化合物与已知化合物的结构。化合物1和2是一对立体异构体,在大环内酯环中并有一个呋喃环,这种环系统在自然界比较稀少。化合物1-4对3株肿瘤细胞株和植物病原真菌没有抑制活性。本结果进一步丰富了该真菌的化学成分研究,暗示特殊生境荒漠植物内生真菌具有产生结构新颖的次级代谢产物的潜力,是发现新活性天然产物的一个新的重要宝库;此外,根据化合物的结构特征与生物活性结果,本文还探讨了这些化合物潜在的生态学功能。     

Prognostic value and immune cell infiltration of hypoxic phenotype‐related gene signatures in glioblastoma microenvironment

Glioblastoma (GBM) is a malignant intracranial tumour with the highest proportion and lethality. It is characterized by invasiveness and heterogeneity. However, the currently available therapies are not curative. As an essential environmental cue that maintains glioma stem cells, hypoxia is considered the cause of tumour resistance to chemotherapy and radiation. Growing evidence shows that immunotherapy focusing on the tumour microenvironment is an effective treatment for GBM; however, the current clinicopathological features cannot predict the response to immunotherapy and provide accurate guidance for immunotherapy. Based on the ESTIMATE algorithm, GBM cases of The Cancer Genome Atlas (TCGA) data set were classified into high‐ and low‐immune/stromal score groups, and a four‐gene tumour environment‐related model was constructed. This model exhibited good efficiency at forecasting short‐ and long‐term prognosis and could also act as an independent prognostic biomarker. Additionally, this model and four of its genes (CLECL5A, SERPING1, CHI3L1 and C1R) were found to be associated with immune cell infiltration, and further study demonstrated that these four genes might drive the hypoxic phenotype of perinecrotic GBM, which affects hypoxia‐induced glioma stemness. Therefore, these might be important candidates for immunotherapy of GBM and deserve further exploration.     

Brassica rapa Polysaccharides Ameliorate CCl4‐Induced Acute Liver Injury in Mice through Inhibiting Inflammatory Apoptotic Response and Oxidative Stress

Brassica rapa L., also called NIUMA, is used empirically in Tibetan medicine for its antioxidant, anti‐inflammatory and antiradiation activities. This study explored the hepatoprotective effects of B. rapa polysaccharides (BRPs) on acute liver injury induced by carbon tetrachloride (CCl₄) in mice and the underlying mechanisms. Mice were treated with CCl₄ after the oral administration of BRPs (55, 110 and 220 mg/kg) or bifendate (100 mg/kg) for 7 days. Blood and liver samples of mice were collected for analysis after 24 h. The ALP, ALT and AST levels and the biological activities of SOD, MDA and GSH?Px were measured. Histopathological changes in the liver were determined through hematoxylin and eosin staining. Moreover, TNF‐α, IL‐1β and IL‐6 expression levels were detected by commercial reagent kits. Finally, Western blot analysis was used to check the relative expression levels of caspase‐3, p‐JAK2 and p‐STAT3. The BRP pre‐treatment significantly decreased the enzymatic activities of ALT, ALP and AST in the serum, markedly increased the activities of SOD and GSH?Px in the liver and reduced the MDA concentration in the liver. BRPs alleviated hepatocyte injury and markedly inhibited the expression of TNF‐α, IL‐1β and IL‐6, also downregulating the CCl₄‐induced hepatic tissue expression of caspase‐3. Furthermore, BRPs inhibited the JAK2/STAT3 signaling pathway in a dose‐dependent manner in the liver. This study demonstrated that BRPs exert hepatoprotective effect against the CCl₄‐induced liver injury via modulating the apoptotic and inflammatory responses and downregulating the JAK2/STAT3 signaling pathway. Therefore, B. rapa could be considered a hepatoprotective medicine.     

An outcome model for human bladder cancer: A comprehensive study based on weighted gene co‐expression network analysis

The precision evaluation of prognosis is crucial for clinical treatment decision of bladder cancer (BCa). Therefore, establishing an effective prognostic model for BCa has significant clinical implications. We performed WGCNA and DEG screening to initially identify the candidate genes. The candidate genes were applied to construct a LASSO Cox regression analysis model. The effectiveness and accuracy of the prognostic model were tested by internal/external validation and pan‐cancer validation and time‐dependent ROC. Additionally, a nomogram based on the parameter selected from univariate and multivariate cox regression analysis was constructed. Eight genes were eventually screened out as progression‐related differentially expressed candidates in BCa. LASSO Cox regression analysis identified 3 genes to build up the outcome model in E‐MTAB‐4321 and the outcome model had good performance in predicting patient progress free survival of BCa patients in discovery and test set. Subsequently, another three datasets also have a good predictive value for BCa patients' OS and DFS. Time‐dependent ROC indicated an ideal predictive accuracy of the outcome model. Meanwhile, the nomogram showed a good performance and clinical utility. In addition, the prognostic model also exhibits good performance in pan‐cancer patients. Our outcome model was the first prognosis model for human bladder cancer progression prediction via integrative bioinformatics analysis, which may aid in clinical decision‐making.     

Absent in melanoma 2 enhances anti‐tumour effects of CAIX promotor controlled conditionally replicative adenovirus in renal cancer

Conditionally replicative adenoviruses (CRAds) were promising approach for solid tumour treatment, but its oncolytic efficiency and toxicity are still not satisfactory for further clinical application. Here, we developed the CAIX promotor (CAIX^promotor)‐controlled CRAd armed with a tumour suppressor absent in melanoma 2 (AIM2) to enhance its oncolytic potency. The CAIX^promotor‐AIM2 adenoviruses (Ad‐CAIX^promotor‐AIM2) could efficiently express E1A and AIM2 in renal cancer cells. Compared with Ad‐CAIX^promotor, Ad‐CAIX^promotor‐AIM2 significantly inhibited cell proliferation and enhanced cell apoptosis and cell killing, thus resulting in the oncolytic efficiency in 786‐O cells or OSRC‐2 cells. To explore the therapeutic effect, various Ads were intratumourally injected into OSRC‐2‐xenograft mice. The tumour growth was remarkably inhibited in Ad‐CAIX^promotor‐AIM2‐treated group as demonstrated by reduced tumour volume and weight with a low toxicity. The inflammasome inhibitor YVAD‐CMK resulted in the reduction of anti‐tumour activity by Ad‐CAIX^promotor‐AIM2 in vitro or in vivo, suggesting that inflammasome activation response was required for the enhanced therapeutic efficiency. Furthermore, lung metastasis of renal cancer mice was also suppressed by Ad‐CAIX^promotor‐AIM2 treatment accompanied by the decreased tumour fossil in lung tissues. These results indicated that the tumour‐specific Ad‐CAIX^promotor‐AIM2 could be applied for human renal cancer therapy. The therapeutic strategy of AIM2‐based CRAds could be a potential and promising approach for the therapy of primary solid or metastasis tumours.     

Engineering Local Coordination Environments of Atomically Dispersed and Heteroatom‐Coordinated Single Metal Site Electrocatalysts for Clean Energy‐Conversion

Carbon‐based heteroatom‐coordinated single‐atom catalysts (SACs) are promising candidates for energy‐related electrocatalysts because of their low‐cost, tunable catalytic activity/selectivity, and relatively homogeneous morphologies. Unique interactions between single metal sites and their surrounding coordination environments play a significant role in modulating the electronic structure of the metal centers, leading to unusual scaling relationships, new reaction mechanisms, and improved catalytic performance. This review summarizes recent advancements in engineering of the local coordination environment of SACs for improved electrocatalytic performance for several crucial energy‐convention electrochemical reactions: oxygen reduction reaction, hydrogen evolution reaction, oxygen evolution reaction, CO₂ reduction reaction, and nitrogen reduction reaction. Various engineering strategies including heteroatom‐doping, changing the location of SACs on their support, introducing external ligands, and constructing dual metal sites are comprehensively discussed. The controllable synthetic methods and the activity enhancement mechanism of state‐of‐the‐art SACs are also highlighted. Recent achievements in the electronic modification of SACs will provide an understanding of the structure–activity relationship for the rational design of advanced electrocatalysts.